In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Maanasa KazaOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0009-0000-4278-9108 Benjamin Varco-MerthVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.
G W McElfreshOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0002-1948-7571 Sebastian BenjaminOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.
Gregory J BoggyOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0002-8283-5620 Morgan ChaunzwaOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0003-3062-0422 Shana FelthamVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0009-0004-5862-5860 Sohita OjhaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0009-0008-4473-7078 Karina BelicaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0009-0001-5925-3657 Andrea N SelsethVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0001-9536-463X Michael NekorchukVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.
Kathleen Busman-SahayVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0002-8549-0023 Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-2381-1151 Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5127-4659 Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-9494-0268 Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0002-9652-6394 Scott G HansenOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0002-9845-6481 Afam OkoyeVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0001-9671-550X Louis J PickerOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0003-0546-398X Benjamin N BimberOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, 97006, USA.ORCID 0000-0001-8092-3080 Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MUpgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MHigh Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0MBill & Melinda Gates Foundation INV-002377NIAID NIH HHS UM1 AI164560NIH HHS 75N91019D00024NIH HHS P51 OD011092NIH HHS S10 OD034224
6 · The paper itselfAbstract
People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can face non-AIDS complications, partially driven by chronic immune activation. To define immune perturbations during ART-suppressed viral infection, we performed longitudinal single-cell transcriptomic and plasma proteomic analysis of rhesus macaques infected with SIVmac239M and ART-treated for 70 weeks. We identified broad, bi-phasic immune changes. Acute infection involves an interferon-driven signature, correlated with viral replication, that largely resolves with viral control. Cell-associated virus correlated with interferon-stimulated genes in most tissues; however, this was blunted in gut-associated lymph nodes, a feature that may contribute to reservoir persistence. Separate alterations manifest 54-66 weeks-post-infection, after 40 weeks of viral suppression, including broad TGF-β and NF-kB signaling and discrete bursts of inflammatory monocytes, largely restricted to bone marrow. These data highlight the biphasic remodeling of long-term ART-suppressed HIV, identifying specific tissues and cell populations with dysregulation, with implications for the treatment of PLWH.
Identifiers
PMID42094348
PMCPMC13142545
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390